Abstract: Nowdays, the curability of childhood acute lymphoblastic leukemia(ALL) has improved dramatically. However, the subgroup of children with refractory/relapsed ALL still presents a dismal prognosis. New trials such as targeted therapy and immunotherapy are used in practice based on a better genomic characterization, and good clinical effect has been achieved. In this article, we review the current new treatments of childhood refractory/relapsed ALL.